SignalXSignalX

TECH Bio-Techne

Q4 2025 10-Q
Filed: Feb 4, 2026Period ending Dec 31, 2025
Health Care
Biological Products, (No Diagnostic Substances)SEC EDGAR
Bio-Techne Overview

Bio-Techne (TECH) 10-Q quarterly report for Q4 2025, filed with SEC EDGAR on Feb 4, 2026 for the fiscal period ending Dec 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q4 2025 10-Q

Management Discussion & Analysis

  • • Revenue $295.9M flat YoY for Q2 FY25; six months $582.4M, down 1% YoY; organic revenue flat in quarter, slight FX and held-for-sale impacts
  • • Operating margin Protein Sciences 39.3% vs 41.2% YoY Q2; Diagnostics 10.4% vs 3.9% YoY Q2, drove margin improvement overall
+3 more insights

Risk Factors

  • • Continued supply chain disruptions risk impacting production schedules carried from 10-K
  • • Dependence on third-party suppliers with potential for raw material shortages carried from 10-K
+2 more insights

Get deeper insights on Bio-Techne

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.